Notes:
A stroke risk reduction of 69% attributable to warfarin was seen when the data from five studies were combined in the pooled analysis. All analyses represented for individual studies are done on an “intention-to-treat” basis.

Notes:
Strokes represent all strokes regardless of suspected etiology. Transient ischemic attacks, systemic emboli and intracranial hemorrhages are not included. Control represents placebo in all studies except BAATAF where 46% of “control” patients received aspirin and 54% received no treatment.

Back

Contents

Next

Acknowledgments:
The content of this presentation was prepared by Dr. Gregory Albers of the Stanford Stroke Center.